BicycleTx Ltd

BicycleTx Ltd

Bicycle Therapeutics is a clinical-stage pharmaceutical company developing a new and differentiated class of medicines based on its proprietary bicyclic peptide (Bicycle®) technology to treat cancer and other diseases underserved by existing therapeutics. The company has multiple investigational medicines in clinical studies, including new approaches that target Nectin-4, a well-validated tumor antigen, and EphA2, a historically undruggable target. The company is also developing potential therapies for radiopharmaceutical use and, through various partnerships, for diseases beyond oncology.

Breast Cancer, Genitourinary Cancer, Lung Cancer, Metastatic Disease, Biomarkers, Clinical Trials, Developmental Therapeutics

Yes